Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
175.9
%Wording
Conditional
How definitive the wording is.Results for this period
Full year2025年1月1日～2025年12月31日ConsolidatedIFRSNet Sales3,467,675Millions of yenYear on year +13.4%Progress 93.8%
Operating profit867,038Millions of yenYear on year +175.9%Progress 94.1%
Ordinary income739,786Millions of yenYear on year +229.8%
Net income attributable to owners of the parent510,175Millions of yenYear on year +184.6%Progress 89.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share287.36円
Operating Margin25
Financial position at period-end
Total assets8,419,240Millions of yen
of which net assets 4,115,389 Millions of yenEquity ratio 48.5%vs. prior year-end +3.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+514,056
Investment-264,986
Financials-475,471
Net change-226,401
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period831,135 Millions of yen
Segment revenue
Tobacco business3,305,40795.4%+14.1%
Processed Food Operations159,5134.6%+1.5%
Segment profit
たばこ事業（調整後営業利益）952,16199.1%+20.3%
加工食品事業（調整後営業利益）8,5890.9%+6.4%
Regional sales
Japan627,0999.0%+2.9%
Overseas expansion2,840,57741.0%+16.1%
Consolidated3,467,67550.0%+13.4%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales3,697,000 Millions of yen (YoY +6.6%)
Operating profit921,000 Millions of yen (YoY +6.2%)
Ordinary incomeNot disclosed
Net income570,000 Millions of yen (YoY +11.7%)
Annual Dividend Forecast¥234 → ¥242（+3.4%）
Payout ratioFiscal year ending December 2025 81.4 / Fiscal year ending December 2026 (forecast) 75.4
Shareholder Return Policy配当性向75％を目安（±5％程度の範囲内で判断）
Factors Behind Changes in Business Performance
売上収益はたばこ事業及び加工食品事業の増収によるもの。調整後営業利益は両事業の増益によるもの。営業利益は、カナダ訴訟に伴う訴訟損失引当金計上影響の剥落及び調整後営業利益の増加によるもの。親会社の所有者に帰属する当期利益は、営業利益の増加が金融損益の悪化及び法人所得税費用の増加を上回ったことによるもの。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name 鳥居薬品株式会社
Material subsequent eventsNo applicable matters.
Impairment loss34,892 Millions of yen
Breakdown of extraordinary income (loss)調整項目（収益） リストラクチャリング収益 13,982 Millions of yen, カナダ訴訟の和解金に係る負債の再測定益 52,883 Millions of yen, Other 1,250 Millions of yen / 調整項目（費用） Restructuring costs 4,068 Millions of yen, Loss on liquidation of subsidiary 27,128 Millions of yen, Other 1,563 Millions of yen
Depreciation and amortization195,899 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for analysts and institutional investors)
Issued Shares at Period-End2,000,000,000 Shares
Treasury Shares at Period-End224,611,666 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年1月1日～2025年12月31日 |
| Net Sales | 3,467,675 Millions of yen (YoY +13.4%) |
| Operating profit | 867,038 Millions of yen (YoY +175.9%) |
| Ordinary income | 739,786 Millions of yen (YoY +229.8%) |
| Profit attributable to owners of the parent | 510,175 Millions of yen (YoY +184.6%) |
| Net income per share | 287.36円 |
| Operating Margin | 25 |
| Equity ratio | End of the current fiscal period 48.5 / End of previous period 45 |
| Total assets | 8,419,240 Millions of yen |
| Net assets | 4,115,389 Millions of yen |
| Cash flows from operating activities | 514,056 Millions of yen |
| Cash flows from investing activities | -264,986 Millions of yen |
| Cash flows from financing activities | -475,471 Millions of yen |
| Cash and cash equivalents at end of period | 831,135 Millions of yen |
| Full-year earnings forecast | Net Sales 3,697,000 Millions of yen (YoY +6.6%) / Operating profit 921,000 Millions of yen (YoY +6.2%) / Ordinary income Not disclosed / Net income 570,000 Millions of yen (YoY +11.7%) |
| Annual Dividend Forecast | ¥234 → ¥242（+3.4%） |
| Payout ratio | Fiscal year ending December 2025 81.4 / Fiscal year ending December 2026 (forecast) 75.4 |
| Shareholder Return Policy | 配当性向75％を目安（±5％程度の範囲内で判断） |
| Segment revenue | Tobacco business 3,305,407 Millions of yen (YoY +14.1%) / Processed Food Operations 159,513 Millions of yen (YoY +1.5%) |
| Segment profit | たばこ事業（調整後営業利益） 952,161 Millions of yen (YoY +20.3%) / 加工食品事業（調整後営業利益） 8,589 Millions of yen (YoY +6.4%) |
| Regional sales | Japan 627,099 Millions of yen (YoY +2.9%) / Overseas expansion 2,840,577 Millions of yen (YoY +16.1%) / Consolidated 3,467,675 Millions of yen (YoY +13.4%) |
| Depreciation and amortization | 195,899 Millions of yen |
| Impairment loss | 34,892 Millions of yen |
| Breakdown of extraordinary income (loss) | 調整項目（収益） リストラクチャリング収益 13,982 Millions of yen, カナダ訴訟の和解金に係る負債の再測定益 52,883 Millions of yen, Other 1,250 Millions of yen / 調整項目（費用） Restructuring costs 4,068 Millions of yen, Loss on liquidation of subsidiary 27,128 Millions of yen, Other 1,563 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name 鳥居薬品株式会社 |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 2,000,000,000 Shares |
| Treasury Shares at Period-End | 224,611,666 Shares |
| Factors Behind Changes in Business Performance | 売上収益はたばこ事業及び加工食品事業の増収によるもの。調整後営業利益は両事業の増益によるもの。営業利益は、カナダ訴訟に伴う訴訟損失引当金計上影響の剥落及び調整後営業利益の増加によるもの。親会社の所有者に帰属する当期利益は、営業利益の増加が金融損益の悪化及び法人所得税費用の増加を上回ったことによるもの。 |
Items this document does not state (2)
Revision to Earnings ForecastOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上収益はたばこ事業及び加工食品事業の増収によるもの。営業利益は、カナダ訴訟に伴う訴訟損失引当金計上影響の剥落と調整後営業利益の増加によるもの。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.